ClinicalTrials.gg
Not yet recruitingNCT06495671AusNanoMEDUpdated Jul 11, 2024

Australasian Nanoparticle-mediated Magnetically Enhanced Diffusion for Ischemic Stroke

An interventional study of Magnetically enhanced diffusion in Ischemic Stroke and Stroke, sponsored by University of Melbourne. Not yet recruiting at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-11.

Sponsored by University of Melbourne · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Ischemic Stroke with a site in Australia — 17 open to participants now, 20 under way, 8 of them phase 3. Ischemic Stroke · Australia.

Planned enrollment
52nd of 55
30 · median 300
Started
2024
with 6 others
No phase
13 of 62
2 open now
Primary completion
2026-12
later than 4 of 19 live
Registered
54th of 62
by date
Lead sponsor
5 of 62
University of Melbourne

Among the 62 studies in Ischemic Stroke with a site in Australia, this one is the 52nd largest by planned enrollment of the 55 interventional ones that give a count, is one of 7 that started in 2024, is one of 13 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 54th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

17 of the 62 studies in Ischemic Stroke with a site in Australia are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Ischemic Stroke with a site in Australia, or all of them as a file.
02

Study summary

Rapidly restoring blood flow to the brain in patients with stroke caused by a blocked blood vessel in the brain is the key to reducing disability. Current treatments often leave small blocked arteries that cannot be safely opened with mechanical clot removal devices. Furthermore, stagnant flow limits access of clot-dissolving medication to the clot. This trial tests iron nanoparticles (similar to iron infused to replace low body stores but injected directly into the brain artery upstream of the blockage) combined with an external rotating magnet that draws the nanoparticles towards the clot, overcoming stagnant blood flow. The aim is to bring fresh blood which contains naturally-occurring clot-dissolving substances, and any clot-dissolving medication that may be circulating, to the surface of the clot with the aim of restoring blood flow to the brain. The trial will recruit up to 30 patients. All will receive injection of nanoparticles via an angiogram (small tube inserted into a leg or arm artery and fed up into the brain artery under Xray control). The procedure takes 30min and the degree of success in opening the artery at the end of procedure is the primary outcome, combined with an absence of symptomatic brain bleeding at 24h.

03

Conditions studied

  • Ischemic Stroke
  • Stroke

Keywords

  • thrombolysis
  • thrombolytic
  • endovascular thrombectomy
  • nanoparticle
  • magnetically enhanced diffusion
  • digital subtraction angiography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients presenting with ischemic stroke within 24 hours of the time they were last known to be well
  • Patient's age is ≥18 years
  • Legal requirements for consent as per local legislative requirements are satisfied.
  • Distal medium vessel intracranial arterial occlusion visible on CT-angiography, MR-angiography or catheter digital subtraction angiography (DSA) in the middle cerebral, anterior or posterior cerebral artery. The occlusion may be primary or secondary (ie following initial mechanical thrombectomy of a large vessel occlusion)

Exclusion criteria

Exclusion Criteria:

  • Intracranial hemorrhage (ICH) identified by CT or MRI
  • Rapidly improving symptoms at the discretion of the investigator
  • Pre-stroke mRS score of ≥ 3 (indicating functional dependence)
  • Frank hypodensity in >1/3 of the affected arterial territory on non-contrast CT
  • CT Perfusion ischemic core volume > 100 ml
  • Known automated implantable cardiac defibrillator, pacemaker, cerebral aneurysm clip, cochlear implant, cranial neurostimulator or other device implant that is incompatible with the external magnetic field
  • Known allergy or sensitivity to iron
  • Known hemochromatosis, or known liver disease such as cirrhosis.
  • Known aortic dissection
  • Suspected septic embolization
  • Contra indication to imaging with contrast agents
  • Pregnant or lactating women
  • Any terminal illness such that patient would not be expected to survive more than 6 months
  • Current participation in another drug or device treatment study
  • Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Magnetically enhanced diffusion

    Intra-arterial iron nanoparticles (4 x 1mg doses delivered every 3 minutes) delivered via microcatheter proximal to site of arterial occlusion(s) with external rotating magnet, total procedure 30min.

    Device: Magnetically enhanced diffusion

Interventions

  • DeviceMagnetically enhanced diffusion

    Iron nanoparticle (intra-arterial) + External magnet workstation

    Also known as: PULSE Nanomed System

06

What researchers measure

Primary outcomes

  1. Proportion of participants with substantial reperfusion at final angiography (15 +/- 5min after final nanoparticle injection) without symptomatic intracranial hemorrhage on CT/MRI at 24h

    * Substantial reperfusion is defined as \>50% reperfusion of the target occluded vessel territory at cerebral angiogram 15 (+/- 5) minutes after completion of the final nanoparticle injection. Target occluded vessel territory is defined based on the angiogram immediately prior to nanoparticle injection, as adjudicated by the core laboratory. * Symptomatic intracranial hemorrhage is defined according to the Heidelberg Classification as new intracranial hemorrhage detected by brain imaging within 24h associated with any of the items below in the absence of an alternative explanation for clinical deterioration: * ≥4 point increase in NIHSS at the time of diagnosis compared to the most recent NIHSS prior to worsening * ≥2 point increase in one NIHSS category * Leading to intubation/hemicraniectomy/external ventricular drain placement or other major medical/surgical intervention

    Time frame: 24 hours +/- 6 hours

Other outcomes

  1. The proportion of participants with >90% reperfusion of the target occluded vessel territory at cerebral angiogram 15 (+/- 5) minutes after completion of the final nanoparticle injection

    - Near-complete reperfusion is defined as \>90% reperfusion of the target occluded vessel territory at cerebral angiogram 15 (+/- 5) minutes after completion of the final nanoparticle injection. Target occluded vessel territory is defined based on the angiogram immediately prior to nanoparticle injection, as adjudicated by the core laboratory

    Time frame: 15 minutes +/- 5 minutes after completion of the final nanoparticle injection

  2. Symptomatic intracranial hemorrhage

    - Symptomatic intracranial hemorrhage is defined according to the Heidelberg Classification as new intracranial hemorrhage detected by brain imaging within 24h associated with any of the items below in the absence of an alternative explanation for clinical deterioration: * ≥4 point increase in NIHSS at the time of diagnosis compared to the most recent NIHSS prior to worsening * ≥2 point increase in one NIHSS category * Leading to intubation/hemicraniectomy/external ventricular drain placement or other major medical/surgical intervention

    Time frame: 24 hours +/- 6 hours

  3. Procedural arterial perforation

    Procedural arterial perforation that results in visible extravasation of contrast into the subarachnoid space

    Time frame: 24 hours +/- 6 hours

  4. Death due to any cause

    Death due to any cause within 90 days

    Time frame: 90 days +/- 7 days

  5. modified Rankin Scale (mRS) at 3 months

    Modified Rankin Scale ranges from 0 (no symptoms of stroke) to 6 (death), high scores indicate worse outcome. Outcome is descriptive and ordinal analysis compared to historical control (adjusted for baseline NIHSS and age).

    Time frame: 90 days +/- 7 days

  6. modified Rankin Scale (mRS) 0-1 or no change from baseline at 3 months

    Modified Rankin Scale ranges from 0 (no symptoms of stroke) to 6 (death), high scores indicate worse outcome. Outcome is descriptive and compared to historical control (adjusted for baseline NIHSS and age).

    Time frame: 90 days +/- 7 days

  7. modified Rankin Scale (mRS) 0-2 or no change from baseline at 3 months

    Modified Rankin Scale ranges from 0 (no symptoms of stroke) to 6 (death), high scores indicate worse outcome. Outcome is descriptive and compared to historical control (adjusted for baseline NIHSS and age).

    Time frame: 90 days +/- 7 days

  8. Early neurological improvement

    8 point reduction in National Institutes of Health Stroke Scale (NIHSS) score or reaching 0-1 at 3 days. NIHSS ranges from 0-42 with higher scores representing more severe stroke. Outcome is descriptive and compared to historical control (adjusted for baseline NIHSS and age).

    Time frame: 3 days +/- 1 day or discharge if earlier

  9. Reperfusion at 24 hours

    Resolution of perfusion lesion (\<5mL region of brain with hypoperfusion defined as Tmax delay \>6 sec) at 24 hours

    Time frame: 24 hours +/- 6 hours

  10. Recanalization at 24 hours

    Resolution of arterial occlusion at 24 hours assessed using the arterial occlusive lesion (AOL) scale 3. AOL ranges from 0 (no recanalization) to 3 (complete recanalization).

    Time frame: 24 hours +/- 6 hours

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Dec 2026, 28 months later.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 28 months is close to that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2024
First posted
Jul 11, 2024
StartEst.
Aug 1, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jul 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06495671
Lead sponsor
University of Melbourne
Collaborators
Monash University, Euphrates Vascular, Inc.
Responsible party
Sponsor
First posted
Jul 11, 2024
Start date
Aug 1, 2024 (estimated)
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 11, 2024

Study contacts

Bruce Campbell, MBBS FRACP
Contact
bruce.campbell@mh.org.au
61393427000
Bruce CV Campbell, MBBS FRACP
principal investigator · University of Melbourne
Ronil V Chandra, MBBS FRANZCR
principal investigator · Monash University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion